These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16188854)

  • 1. Screening for congenital cataracts: a cost-consequence analysis of eye examination at maternity wards in comparison to well-baby clinics.
    Magnusson G; Persson U
    Acta Paediatr; 2005 Aug; 94(8):1089-95. PubMed ID: 16188854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of screening procedures for congenital cataracts.
    Magnusson G; Jakobsson P; Kugelberg U; Lundvall A; Maly E; Tornqvist K; Abrahamsson M; Andreasson B; Borres MP; Broberger U; Hellström-Westas L; Kornfält R; Nelson N; Sjöstrand J; Thiringer K
    Acta Paediatr; 2003 Dec; 92(12):1468-73. PubMed ID: 14971800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congenital cataract screening in maternity wards is effective: evaluation of the Paediatric Cataract Register of Sweden.
    Magnusson G; Bizjajeva S; Haargaard B; Lundström M; Nyström A; Tornqvist K
    Acta Paediatr; 2013 Mar; 102(3):263-7. PubMed ID: 23205674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cataract in children.
    Foster A; Gilbert C
    Acta Paediatr; 2003 Dec; 92(12):1376-8. PubMed ID: 14971784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Screening for congenital cataract is best done at the obstetrical department. Complementary examination at the child health center is recommended].
    Magnusson G; Thiringer K
    Lakartidningen; 2002 Feb; 99(7):620-5. PubMed ID: 11887706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
    Arrospide A; Rue M; van Ravesteyn NT; Comas M; Soto-Gordoa M; Sarriugarte G; Mar J
    BMC Cancer; 2016 Jun; 16():344. PubMed ID: 27251556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Pediatric Cataract Register (PECARE): analysis of age at detection of congenital cataract.
    Haargaard B; Nyström A; Rosensvärd A; Tornqvist K; Magnusson G
    Acta Ophthalmol; 2015 Feb; 93(1):24-6. PubMed ID: 25613125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
    Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
    Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of population-based vascular disease screening and intervention in men from the Viborg Vascular (VIVA) trial.
    Søgaard R; Lindholt JS
    Br J Surg; 2018 Sep; 105(10):1283-1293. PubMed ID: 29691840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
    Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
    Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective cost-effectiveness analysis of screening mammography.
    Stout NK; Rosenberg MA; Trentham-Dietz A; Smith MA; Robinson SM; Fryback DG
    J Natl Cancer Inst; 2006 Jun; 98(11):774-82. PubMed ID: 16757702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of cataract surgery in the second eye.
    Busbee BG; Brown MM; Brown GC; Sharma S
    Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
    Yoshimura M; Moriwaki K; Noto S; Takiguchi T
    Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.
    Yarnoff BO; Hoerger TJ; Simpson SK; Leib A; Burrows NR; Shrestha SS; Pavkov ME;
    BMC Nephrol; 2017 Mar; 18(1):85. PubMed ID: 28288579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of tandem mass spectrometry screening in California.
    Feuchtbaum L; Cunningham G
    Pediatrics; 2006 May; 117(5 Pt 2):S280-6. PubMed ID: 16735254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis.
    Danese MD; Powe NR; Sawin CT; Ladenson PW
    JAMA; 1996 Jul 24-31; 276(4):285-92. PubMed ID: 8656540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
    Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
    Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Lung Cancer Screening in Canada.
    Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
    JAMA Oncol; 2015 Sep; 1(6):807-13. PubMed ID: 26226181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.
    Hofmarcher T; Borg S
    J Med Econ; 2015; 18(7):492-501. PubMed ID: 25766863
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.